Repligen Corporation(RGEN) Stock Research - Grey Stern Research

Repligen Corporation (RGEN) Stock Analysis

$145.78 (2.64%)

RGEN Financial Performance


Use the table below to view Repligen Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $142.03 -
52 Week Low $110.45 -
52 Week High $211.13 -
Market Cap $8.0 Billion 9/14
Gross Margin 45% 11/14
Profit Margin 2% 11/14
EBITDA margin 13% 11/14
Q2 - 2024 Revenue $154.1 Million 13/14
Q2 - 2024 Earnings $3.3 Million 11/14
Q2 - 2024 Free Cash Flow $34.8 Million 12/14
Trailing 4 Quarters Revenue $602.4 Million 13/14
Trailing 4 Quarters Earnings -$1.9 Million 11/14
Quarterly Earnings Growth -83% 12/14
Annual Earnings Growth -102% 12/14
Quarterly Revenue Growth -3% 11/14
Annual Revenue Growth -15% 12/14
Cash On Hand $809.1 Million 5/14
Short Term Debt $81.6 Million 7/14
Long Term Debt $517.7 Million 11/14

Repligen Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Repligen Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 11/14
PS 13.21 2/14
PB 4.00 7/14
PC 9.83 10/14
Liabilities to Equity 0.44 11/14
ROA 0.00 11/14
ROE 0.00 11/14
Current Ratio 3.27 4/14
Quick Ratio 0.92 2/14
Long Term Debt to Equity 0.26 10/14
Debt to Equity 0.37 9/14
Burn Rate 21.41 3/14
Cash to Cap 0.10 5/14
CCR 10.48 1/14
EV to EBITDA 390.20 1/14
EV to Revenue 13.10 2/14

Company Details

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

CEO: Mr. Anthony Hunt

Website: https://www.repligen.com

Address: 41 Seyon St Bldg 1 Ste 100 Waltham, MASSACHUSETTS

Exchange: NASDAQ Global Select

Industry: Medical Instruments & Supplies

Repligen Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Repligen Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Becton, Dickinson and Company BDX $67.8 Billion
Hologic, Inc. HOLX $19.1 Billion
Intuitive Surgical, Inc. ISRG $174.1 Billion
ResMed Inc. RMD $35.7 Billion
The Cooper Companies, Inc. COO $22.1 Billion
Haemonetics Corporation HAE $3.8 Billion
Teleflex Incorporated TFX $11.6 Billion
West Pharmaceutical Services, Inc. WST $22.6 Billion
Merit Medical Systems, Inc. MMSI $5.8 Billion
AngioDynamics, Inc. ANGO $310.1 Million
ICU Medical, Inc. ICUI $4.4 Billion
AptarGroup, Inc. ATR $10.4 Billion
Envista Holdings Corporation NVST $3.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RGEN Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 154.1 Million $3.3 Million
Q1 2024 $ 151.3 Million $2.1 Million
Q4 2023 $ 155.7 Million -$25.5 Million
Q3 2023 $ 141.2 Million $18.2 Million
Q2 2023 $ 159.2 Million $20.1 Million
Q1 2023 $ 182.7 Million $28.8 Million
Q4 2022 $ 186.8 Million $48.7 Million
Q3 2022 $ 200.7 Million $40.4 Million

View All

RGEN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $809.1 Million $2.9 Billion $742.9 Million $2.0 Billion
Q1 2024 $780.6 Million $2.8 Billion $737.7 Million $2.0 Billion
Q4 2023 $751.3 Million $2.8 Billion $711.8 Million $2.0 Billion
Q3 2023 $630.8 Million $2.5 Billion $419.9 Million $464.3 Million
Q2 2023 $603.7 Million $2.5 Billion $422.8 Million $446.2 Million
Q1 2023 $516.6 Million $2.5 Billion $420.7 Million $426.1 Million
Q4 2022 $523.5 Million $2.5 Billion $423.0 Million $397.3 Million
Q3 2022 $573.4 Million $2.5 Billion $418.5 Million $1.8 Billion

View All

RGEN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $34.8 Million -$7.4 Million $28.5 Million
Q1 2024 $36.3 Million -$8.4 Million $29.3 Million
Q4 2023 $20.7 Million -$8.4 Million $120.5 Million
Q3 2023 $24.5 Million $0 $24.5 Million
Q2 2023 $25.5 Million $0 $25.5 Million
Q1 2023 $1.7 Million -$9.4 Million -$6.8 Million
Q4 2022 $40.5 Million -$21.4 Million -$49.9 Million
Q3 2022 $23.7 Million -$40.7 Million -$23.1 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions